Member Info for inanaco

because you keep referring to 2017 AGM .. what has that got to do with Scancell acquiring this current technology ?

ue 17/03/2015, 17:21 You I am well this is from my university group. Lind Prof Lindy Durrant The University of Nottingham Academic Clinical Oncology City Hospital Campus Hucknall Road Nottingham NG5 1PB and that is the email confirming that this data was not Scancells .

Boomorbust ... Lindy in 2017 could not refer to glycosylation as Scancells ... it was not it belonged to the university look at the names on the paper and cross ref them to Scancell staff Monoclonal Antibodies Targeting LecLex-Related Glycans with Potent Anti-Tumor Activity Chua X Jia, Mireille Vankemmelbeke, Richard S McIntosh, Philip A Clarke, Robert Moss, Tina Parsons, Ian Spendlove, Abid M Zaitoun, Srinivasan Madhusudan and Lindy G Durrant

Ref your 16.41 boom it was in your own link .... posted on the 12th of April http://journals.sagepub.com/doi/full/10.1177/2515135518768769 """Aberrant N-acetylglucosamine (O-GlcNAc) can correlate with augmented cancer cell proliferation, survival, invasion and metastases. Elution of MHC-I peptides from cancer cells have identified numerous O-GlcNAc-modified epitopes. These peptides can stimulate multifunctional T-cell responses to the glycosylated but not the unglycosylated peptide and may form the basis for future cancer vaccines """ and In theory, combinations of a select few citrullinated peptides could be used to target all major solid cancers resulting in a step change in the approach to treating tumours. In addition to citrullination, other stress-induced post-translational modifications (siPTM) have been observed within MHC-bound peptides.26,27 Our overarching hypothesis is that these vaccines based upon siPTM of proteins will elicit new or boost pre-existing immunity that will eliminate tumours with a low T-cell infiltrate.

sorry that refers to your 14.15 boom ...

well i think there may well be, because this particular PTM as far as i can see is normal ......... what lindy has not said that these sugars only appear after stress ... thus an SI PTM .... stress induced as per previous discussion may well be to follow.

so targeting a cancer that's cold .... could be a step approach ... ie Bispecific monoclonal antibody attached to cold cancers displaying sugars .... which is why the 54% on pancreatic raised my eyebrows. Clearly i am not a scientists .. but by reasoning the building blocks ..you can make sense from it, which appears plausible. However the best speech will be Lindy Durrant on the subject ... lets see what the Grand challenge unfolds because IMHO this platform could play a key role as an initiator with all worked paid for by CRUK its going to be very interesting because the Golden Goose is victory over the hardest to treat .......... it means all the other cancers are technically possible with existing technology developed within the Modi 3 research

Then you have to think how that helps Moditope ... again bispecfic MABS are very big business Bispecific monoclonal antibody. A bispecific monoclonal antibody (BsMAb, BsAb) is an artificial protein that can simultaneously bind to two different types of antigen. BsMabs can be manufactured in several structural formats, and current applications have been explored for cancer immunotherapy and drug delivery. Anti-glycan antibodies can conceivably be used in a number of alternative settings for instance as carriers for drug conjugates or in a bispecific format to redirect T-cells. In all these settings absence of cross-reactivity with normal healthy tissues is warranted in order to avoid off-target toxicity. The immunohistochemical analysis of our Le antibodies revealed strong staining of a large percentage of tumor tissues covering colorectal, gastric, pancreatic, non-small cell lung, and ovarian cancer tissues, combined with no cross-reactivity with most normal tissues including lung, liver (parenchyma), heart, brain, and kidney. We observed some (low to moderate) normal cross-reactivity (mainly with a subset of gastrointestinal tissues), but it is unclear whether this represents the same target as the tumor tissues.

yes i understood that which is why I also introduced immunobody back into the because its also an advanced antibody. the confusing bit which i was trying to interpret was "together" with singular use of the word Platform which means the glycans plus cytotoxic action Mab are combined Together these offer a complementary platform to Scancell's existing cancer immunotherapy platforms, ImmunoBody� and Moditope�.

To close Off that 9am buy of �15k .... interesting, is stock short already

well i found my cash ... just waiting

Some big buyers sucking up the shares

The government announced in the 2011 budget that it would consult on options to provide new support for seed investment. As a consequence the seed enterprise investment scheme (SEIS) was introduced from 6 April 2012 to encourage investment in new start-up companies. In the 2014 budget, the government announced that the SEIS was being made permanent. In the 2015 budget, the government announced an amendment to tax-advantaged venture capital schemes. There were a number of revisions including: in addition to the existing cap on annual investments of �5 million, a new cap applies on the total amount of investments a company may raise under EIS, VCT or other risk finance investment, of �15 million, except for knowledge-intensive companies For knowledge-intensive companies, the cap on the total amount of investments is �20 million, and the limit on employees is raised from 250 to 500 employees. It was announced in the 2015 autumn statement that effective from 30 November 2015, the provision of reserve energy generating capacity and the generation of renewable energy benefiting from other government support by community energy organisations are no longer qualifying activities for VCT or social investment tax relief.

but its the same tax status

I think that is way to complicated to discuss here, as PD1 on its own is a check point inhibitor, as such it does not produce a memory effect, but that does not mean the patients own immune system does not create that memory effect, as such its so "individual" to each response, its best left alone.

Oxford Technology VCT Plc: notice to shareholders: HMRC set aside decision of 7 March 2014 to withdraw VCT approval and will reconsider afresh the issue of withdrawal of VCT approval Following consideration of a legal opinion given on behalf of the Oxford VCTs by Graham Aaronson QC and Jonathan Bremner of Counsel, instructed by Joseph Hage Aaronson LLP, HMRC have today notified Joseph Hage Aaronson LLP that the decision dated 7 March 2014 to withdraw venture capital trust approval from Oxford Technology VCT Plc ("OT1") and Oxford Technology 3 VCT Plc ("OT3") has been set aside.

its an EIS fund, so it cannot just add ... the same happened to OXT EIS fund they bought shares in Scancell and HMRC went nuts, forcing a sell off a few years back

SCIB1 plus keytruda trial is the Key to putting Scancell on the map... winning the �20m grant from CRUK is the icing on the cake. It validates Scancell research team as the best in this field, and to lead the likes of ISA pharma, BioNtech and Roche .... nobody can dispute Lindy Durrants credentials ..

The growing portfolio is way more important than a bit of share dilution .... because the Cash generated has an effect and that is what you can try and value now as both platforms enter trial excited you should be High avidity T cell generated by immunobody .... with the market leader keytruda Success = SCIB2 success and the value and interest of the pipeline will grow Moditope ... wow ! ... its mind blowing because with own all the epitopes ...

Unlike drugs that act directly ....... Scancells products do not Its the immune system that does all the work ........... as long as you know how to program it, the consequence is that the bodies only natural defence system does the rest. Unlike our competition ... Lindy discovered the best T cells to generate and how best to program them. Which is why you see this very complex Antibody called immunobody doing just that ... many of our competition need adjuvants to try and slew from low avidity to high avidity and really have not nailed the perfect killing machine. Moditope uses adjuvants in a different way, its not looking to change the avidity but increase the TH1 which is pro inflammatory T cell ... so that the immune response is very aggressive, the more aggressive the more the Expressed epitope that moditope is looking for is exposed .... which is why "interferon Gamma" which is the cytokine responsible is so important ... If elevated levels are seen in patients you know you have success ... I really am excited about the science, and i will say again, no other Bio Share has this level of expertise and a pipeline to match. Its a pity the stock market sleeps .... while a giant in the making quietly gets on with it.